Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02525939 · ClinicalTrials.gov registry record · Phase 3
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
A Phase 3 study, sponsored by DalCor Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,147
- Enrollment target
NCT02525939 is a Phase 3 study that has completed, run by DalCor Pharmaceuticals. The registered enrollment target is 6,147 participants.
The verdict
NCT02525939, a Phase 3 study, has completed, sponsored by DalCor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,147 participants
- Enrollment target
Study Summary
A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in the hospital and will continue following release from the hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (4-12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.
Interventions
- DRUG Placebo
- DRUG dalcetrapib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,147 participants |
| Start Date | 2016-04 |
| Est. Completion | 2021-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02525939
The ClinicalTrials.gov registry entry for NCT02525939 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DalCor Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02525939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02525939 about?
NCT02525939 is a clinical study titled "Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS". A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in t...
What is the current status of trial NCT02525939?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,147 participants. The study started on 2016-04. Estimated completion is 2021-10.
What interventions are being tested in trial NCT02525939?
The interventions under investigation include: Placebo (DRUG), dalcetrapib (DRUG).
Who is sponsoring clinical trial NCT02525939?
This trial is sponsored by DalCor Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.